Recent advances in DNA-sequencing technology have increased the speed of data acquisition. However, without accompanying improvements in the ability to select relevant portions of the genome, the technology cannot achieve its full potential in studying the relationships between genes and diseases. The Agilent genome-partitioning portfolio, which is currently in development, holds great potential for eliminating this bottleneck by enabling users to efficiently design and acquire ready-to-use, custom mixtures of biotinylated long RNA probes in a single tube.
Agilent plans to offer kits containing custom mixtures of long biotinylated RNA molecules that can efficiently capture 5-10 megabases of genomic DNA sample in a single tube.
Yvonne Linney, Agilent’s vice president and general manager, Genomics, said: “This work to eliminate the sample-preparation bottleneck of next-generation sequencing will greatly accelerate our understanding of how genes operate.”